Treatment of Guillain-Barré syndrome with mycophenolate mofetil: A pilot study [5]

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 9, 2007, Pages 1012-1013

  Garssen, M P J ^a   Van Koningsveld, R ^a   Van Doorn, P A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ABDOMINAL DISEASE; ADULT; AGED; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG FATALITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GUILLAIN BARRE SYNDROME; HUMAN; KIDNEY FAILURE; LETTER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; THROMBOSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 34548184674     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.102731     Document Type: Letter

References (7)

1. Hughes RA, Raphael JC, Swan AV, et al. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2004;1:CD002063.
2. Van Koningsveld R, Schmitz PI, Meché FG, et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004;363:192-6.
3. Willison HJ. The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 2005;10:94-112.
4. Vermersch P, Stojkovic T, de Seze J. Mycophenolate mofetil and neurological diseases. Lupus 2005;14(Suppl 1):S42-5.
5. Cauchy V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001;56:94-6.
6. Gorson KC, Amato AA, Ropper AH. Efficacy of mycophenolate mofetil in patients with chronic immune demyelinating polyneuropathy. Neurology 2004;63:715-17.
7. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(Suppl): S21-4.